BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX

BioCryst Pharmaceuticals stock price today

$8.21
+0.50
+6.49%
Financial Health
0
1
2
3
4
5
6
7
8
9

BioCryst Pharmaceuticals stock price monthly change

+7.83%
month

BioCryst Pharmaceuticals stock price quarterly change

+7.83%
quarter

BioCryst Pharmaceuticals stock price yearly change

+24.56%
year

BioCryst Pharmaceuticals key metrics

Market Cap
1.54B
Enterprise value
2.02B
P/E
-6.3
EV/Sales
7.47
EV/EBITDA
-14.08
Price/Sales
5.86
Price/Book
-5.39
PEG ratio
0.21
EPS
-1.06
Revenue
355.39M
EBITDA
-77.08M
Income
-208.58M
Revenue Q/Q
34.87%
Revenue Y/Y
22.68%
Profit margin
-91.24%
Oper. margin
-54.81%
Gross margin
97.57%
EBIT margin
-54.81%
EBITDA margin
-21.69%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

BioCryst Pharmaceuticals stock price history

BioCryst Pharmaceuticals stock forecast

BioCryst Pharmaceuticals financial statements

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Profit margin
Jun 2023 82.49M -75.32M -91.31%
Sep 2023 86.74M -36.14M -41.67%
Dec 2023 93.40M -61.73M -66.09%
Mar 2024 92.76M -35.37M -38.14%
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Analyst Estimates
Mar 2024 92.76M -35.37M -38.14%
Sep 2025 122.36M -7.04M -5.76%
Oct 2025 125.94M -10.30M -8.18%
Dec 2025 137.28M -1.03M -0.75%
  • Analysts Price target

  • Financials & Ratios estimates

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Debt to assets
Jun 2023 529885000 918.59M 173.36%
Sep 2023 -685518000 933.91M -136.23%
Dec 2023 516960000 972.48M 188.12%
Mar 2024 467892000 944.05M 201.77%
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Cash Flow
Jun 2023 -18.81M -19.03M 29.35M
Sep 2023 -19.89M 23.11M 1.22M
Dec 2023 -8.91M -28.47M -3.17M
Mar 2024 -53.68M 28.75M -1.04M

BioCryst Pharmaceuticals alternative data

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Employee count
Sep 2023 531
Oct 2023 531
Nov 2023 531
Dec 2023 531
Jan 2024 531
Feb 2024 531
Mar 2024 536
Apr 2024 536
May 2024 536
Jun 2024 536
Jul 2024 536

BioCryst Pharmaceuticals other data

70.82% -29.18%
of BCRX is owned by hedge funds
126.85M +8.98M
shares is hold by hedge funds

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Insider trades (number of shares)
Period Buy Sel
May 2024 183601 0
Jun 2024 0 19987
Dec 2024 0 7000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
HUTSON NANCY J director
Common Stock 7,000 $7.54 $52,780
Sale
MCKEE AMY E director
Common Stock 8,600 $6.32 $54,352
Sale
SANDERS MACHELLE director
Common Stock 4,689 $6 $28,134
Sale
HEGGIE THERESA director
Common Stock 6,698 $6.11 $40,925
Purchase
LEVIN ALAN G director
Common Stock 7,861 $6.36 $49,996
Purchase
ASELAGE STEVE director
Common Stock 2,500 $6.4 $16,000
Purchase
HUTSON NANCY J director
Common Stock 5,000 $6.38 $31,900
Purchase
MILANO VINCENT director Common Stock 15,000 $6.25 $93,750
Purchase
DOYLE ANTHONY officer: Chief Financial Officer
Common Stock 36,300 $5.57 $202,191
Purchase
THACKRAY HELEN M. officer: Chief R&D Officer
Common Stock 30,000 $5.86 $175,800
Patent
Application
Filling date: 2 Sep 2021 Issue date: 30 Jun 2022
Application
Filling date: 8 Apr 2020 Issue date: 26 May 2022
Application
Filling date: 13 Jul 2021 Issue date: 31 Mar 2022
Application
Filling date: 21 Oct 2021 Issue date: 10 Feb 2022
Grant
Filling date: 10 Apr 2020 Issue date: 25 Jan 2022
Grant
Filling date: 24 Mar 2020 Issue date: 21 Dec 2021
Grant
Filling date: 24 Mar 2020 Issue date: 7 Dec 2021
Grant
Filling date: 16 Aug 2019 Issue date: 16 Nov 2021
Grant
Filling date: 6 Feb 2020 Issue date: 14 Sep 2021
Grant
Filling date: 1 May 2019 Issue date: 7 Sep 2021
Monday, 9 December 2024
seekingalpha.com
Wednesday, 4 December 2024
globenewswire.com
Monday, 18 November 2024
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Monday, 4 November 2024
seekingalpha.com
zacks.com
Wednesday, 23 October 2024
zacks.com
Monday, 21 October 2024
globenewswire.com
Monday, 14 October 2024
globenewswire.com
Monday, 7 October 2024
zacks.com
Thursday, 3 October 2024
globenewswire.com
Wednesday, 2 October 2024
globenewswire.com
Monday, 30 September 2024
globenewswire.com
Tuesday, 17 September 2024
globenewswire.com
Friday, 6 September 2024
globenewswire.com
Wednesday, 4 September 2024
globenewswire.com
Thursday, 22 August 2024
globenewswire.com
Monday, 5 August 2024
seekingalpha.com
zacks.com
zacks.com
globenewswire.com
Friday, 2 August 2024
globenewswire.com
Tuesday, 30 July 2024
investorplace.com
Monday, 29 July 2024
zacks.com
Monday, 22 July 2024
globenewswire.com
Sunday, 21 July 2024
seekingalpha.com
Thursday, 18 July 2024
zacks.com
zacks.com
Tuesday, 9 July 2024
globenewswire.com
  • What's the price of BioCryst Pharmaceuticals stock today?

    One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $8.21.

  • When is BioCryst Pharmaceuticals's next earnings date?

    Unfortunately, BioCryst Pharmaceuticals's (BCRX) next earnings date is currently unknown.

  • Does BioCryst Pharmaceuticals pay dividends?

    No, BioCryst Pharmaceuticals does not pay dividends.

  • How much money does BioCryst Pharmaceuticals make?

    BioCryst Pharmaceuticals has a market capitalization of 1.54B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.37% to 331.41M US dollars.

  • What is BioCryst Pharmaceuticals's stock symbol?

    BioCryst Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "BCRX".

  • What is BioCryst Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of BioCryst Pharmaceuticals?

    Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are BioCryst Pharmaceuticals's key executives?

    BioCryst Pharmaceuticals's management team includes the following people:

    • Mr. Jon P. Stonehouse Chief Executive Officer, Pres & Executive Director(age: 64, pay: $1,120,000)
    • Dr. William P. Sheridan Chief Medical Officer & Senior Vice President(age: 70, pay: $786,970)
    • Dr. Yarlagadda S. Babu Chief Discovery Officer(age: 72, pay: $682,620)
    • Dr. Helen M. Thackray FAAP, M.D. Chief R&D Officer(age: 57, pay: $55,000)
  • How many employees does BioCryst Pharmaceuticals have?

    As Jul 2024, BioCryst Pharmaceuticals employs 536 workers.

  • When BioCryst Pharmaceuticals went public?

    BioCryst Pharmaceuticals, Inc. is publicly traded company for more then 31 years since IPO on 4 Mar 1994.

  • What is BioCryst Pharmaceuticals's official website?

    The official website for BioCryst Pharmaceuticals is biocryst.com.

  • Where are BioCryst Pharmaceuticals's headquarters?

    BioCryst Pharmaceuticals is headquartered at 4505 Emperor Boulevard, Durham, NC.

  • How can i contact BioCryst Pharmaceuticals?

    BioCryst Pharmaceuticals's mailing address is 4505 Emperor Boulevard, Durham, NC and company can be reached via phone at +91 98591302.

BioCryst Pharmaceuticals company profile:

BioCryst Pharmaceuticals, Inc.

biocryst.com
Exchange:

NASDAQ

Full time employees:

536

Industry:

Biotechnology

Sector:

Healthcare

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

4505 Emperor Boulevard
Durham, NC 27703

CIK: 0000882796
ISIN: US09058V1035
CUSIP: 09058V103